Esperion Therapeutics Inc share price logo

Esperion Therapeutics Inc

NASDAQ: ESPR

Small Cap

$3.13

as on

Esperion Therapeutics Inc Stock Performance

as on May 23, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.12
    $3.14
    downward going graph

    0.32%

    Downside

    0.32%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.76
    $4.18
    downward going graph

    75.72%

    Downside

    33.39%

    Upside

    downward going graph

Esperion Therapeutics Inc share price movements today

Previous Close
$3.13
Open
$3.13
Volume
6.0M
Day's Low - High
$3.12 - $3.14
52 Week Low - High
$0.76 - $4.18

Esperion Therapeutics Inc Historical Returns

1 Month Return
+ 63.87 %
3 Month Return
-5.15 %
1 Year Return
+ 296.05 %
3 Year Return
+ 98.1 %
5 Year Return
-84.56 %

Esperion Therapeutics Inc Stock Fundamentals & Key Indicators

Check Esperion Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$805.8M

EPS (TTM)

-0.21

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-4.78

EBITDA

-

Revenue (TTM)

-

Profit Margin

-1.78%

Return On Equity TTM

-260.79%

Esperion Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Esperion Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$805.8M-84.56%NA-1.78%
BUY$24.0BNA20.940.62%
HOLD$19.3B7.16%NA-2.04%
BUY$41.3BNA18.6415.11%
BUY$33.6B-54.61%13.1328.04%

Stock Returns calculator for Esperion Therapeutics Inc Stock including INR - Dollar returns

The Esperion Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Esperion Therapeutics Inc investment value today

Current value as on today

₹4,45,526

Returns

₹3,45,526

(+345.53%)

Returns from Esperion Therapeutics Inc Stock

₹2,96,203 (+296.2%)

Dollar Impact

₹49,323 (+49.32%)

Analyst Recommendation on Esperion Therapeutics Inc Stock

Based on 14 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 14 analysts, 71.43% of analysts recommend a 'BUY' rating for Esperion Therapeutics Inc. Average target price of $3.19

Esperion Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Esperion Therapeutics Inc.

What analysts predicted

1.88%UPSIDE

Target Price

$3.19

Current Price

$3.13

Analyzed by

14 Analysts

Target

$3.19

Esperion Therapeutics Inc target price $3.19, a slight upside of 1.88% compared to current price of $3.13. According to 14 analysts rating.

Indian Investors' Interest in Esperion Therapeutics Inc Stock

Search interest for Esperion Therapeutics Inc Stock has increased by 657% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:657% versus previous 30 day period

Esperion Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
32
137
73
51
69
64
82
87
168
80
Gross Profit
20
127
58
34
43
33
53
31
140
45
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-56
61
-61
-29
-21
-40
-12
-31
61
-25
Net Profit Margin
-174.71%
44.30%
-83.87%
-57.18%
-30.85%
-62.24%
-15.45%
-35.89%
36.71%
-31.45%

Esperion Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
184
148
227
78
75
116
332
403
Gross Profit
0
0
184
148
225
64
48
73
263
273
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-74
-166
-201
-97
-143
-269
-233
-209
-51
-22
Net Profit Margin
0.00%
0.00%
-109.40%
-65.49%
-63.09%
-343.04%
-309.58%
-179.87%
-15.57%
-5.63%

Global Institutional Holdings in Esperion Therapeutics Inc

Funds
Holdings
D. E. Shaw & Co LP
2.68%
Marshall Wace Asset Management Ltd
2.13%
Bank of America Corp
0.41%
AIGH Capital Management, LLC
1.55%
BlackRock Inc
6.87%

Esperion Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 06 November

    Fri, 00:00 AM

    -

    Analysts maintain Buy ratings for Esperion, citing strong financial performance and growth potential despite insider selling.

    Fri, 06:29 AM

    -

    Esperion reports 69% revenue growth in Q3 2025, driven by U.S. product revenue and strategic marketing initiatives.

Insights on Esperion Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ESPR stock has moved up by 63.9%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ESPR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ESPR has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 168.44M → 80.10M (in $), with an average decrease of 52.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 61.83M → -25.19M (in $), with an average decrease of 140.8% per quarter

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
OrganisationEsperion Therapeutics Inc
Headquarters3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Sheldon L. Koenig M.B.A.
E-voting on sharesClick here to vote

Key Management of Esperion Therapeutics Inc

Name

Title

Mr. Sheldon L. Koenig M.B.A.

President, CEO & Director

Mr. John B. Harlow Jr.

Chief Commercial Officer

Mr. Glenn P. Brame

Chief Technical Operations Officer

Ms. Betty Jean Swartz

Chief Business Officer

LeAnne Bloedon M.S.

VP & Head of Development

Dr. Stephen Pinkosky

Vice President of Drug Discovery of Early Pre-Clinical Development

Mr. Benjamin Halladay M.B.A.

Chief Financial Officer

Mr. Benjamin O. Looker J.D.

Chief Legal & Corporate Affairs Officer

Tiffany Aldrich M.B.A.

Associate Director of Corporate Communications

FAQs

What is Esperion Therapeutics Inc share price today?

Esperion Therapeutics Inc share price today is $3.13 as on at the close of the market. Esperion Therapeutics Inc share today touched a day high of $3.14 and a low of $3.12.

What is the 52 week high and 52 week low for Esperion Therapeutics Inc share?

Esperion Therapeutics Inc share touched a 52 week high of $4.18 on and a 52 week low of $0.76 on . Esperion Therapeutics Inc stock price today i.e. is closed at $3.13,which is 25.03% down from its 52 week high and 311.84% up from its 52 week low.

What is Esperion Therapeutics Inc's market capitalisation today?

Esperion Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Esperion Therapeutics Inc Stock (ESPR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Esperion Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Esperion Therapeutics Inc Shares that will get you 0.4792 shares as per Esperion Therapeutics Inc share price of $3.13 per share as on May 23, 2026 at 8:46 am IST.

What is the minimum amount required to buy Esperion Therapeutics Inc Stock (ESPR) from India?

Indian investors can start investing in Esperion Therapeutics Inc (ESPR) shares with as little as ₹95.68 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.80 in Esperion Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Esperion Therapeutics Inc share’s latest price of $3.13 as on May 23, 2026 at 8:46 am IST, you will get 3.1949 shares of Esperion Therapeutics Inc. Learn more about fractional shares .

What are the returns that Esperion Therapeutics Inc has given to Indian investors in the last 5 years?

Esperion Therapeutics Inc stock has given -84.56% share price returns and 32.09% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?